SEC Company Response from SciSparc Ltd. (SPRC) (CIK 0001611746) (SPRC) — Dec 16, 2016

SciSparc Ltd. (SPRC) (CIK 0001611746)
Date: Dec. 16, 2016 · CIK: 0001611746 · Accession: 0001213900-16-019476

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-214458

Date

Dec. 16, 2016

Author

Therapix

Form

CORRESP

Company

SciSparc Ltd. (SPRC) (CIK 0001611746)

Letter

Therapix Biosciences Ltd.

Azrieli Center (Square Tower)

Tel-Aviv 6702501, Israel

December 16, 2016

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E.

Washington, DC 20549

RE: Therapix Biosciences Ltd. (CIK: 0001611746)

Registration Statement No. 333-214458 on Form F-1 (the “Registration Statement”)

Ladies and Gentlemen:

Therapix Biosciences Ltd. (the “Registrant”) hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may become effective on December 20, 2016 at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable.

The Registrant understands that the Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act as they relate to the proposed public offering of the securities specified in the Registration Statement.

Very
truly yours,
Therapix
Biosciences Ltd.

Show Raw Text

CORRESP
1
filename1.htm

Therapix
Biosciences Ltd.

5
Azrieli Center (Square Tower)

Tel-Aviv
6702501, Israel

December
16, 2016

VIA
EDGAR

Securities
and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
DC 20549

    RE:
    Therapix
    Biosciences Ltd. (CIK: 0001611746)

    Registration
    Statement No. 333-214458 on Form F-1 (the “Registration Statement”)

Ladies
and Gentlemen:

Therapix
Biosciences Ltd. (the “Registrant”) hereby requests acceleration of the effectiveness of the above-referenced
Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”),
so that it may become effective on December 20, 2016 at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable.

The
Registrant understands that the Commission will consider this request for acceleration of the effective date of the Registration
Statement as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act as they
relate to the proposed public offering of the securities specified in the Registration Statement.

    Very
    truly yours,

    Therapix
    Biosciences Ltd.

    By:
    /s/
    Dr. Elran Haber

    Dr.
    Elran Haber, Chief Executive Officer

SecProbe.io